NCT06847438Completed
Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure
Source: ClinicalTrials.gov · Last updated 28 Jul 2026
Brief summary (registry, in English)
Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) have shown promise for increasing use of GDMT. However, these tools have not been broadly implemented within large health systems. The goal of this study is to see if using these tools broadly within cardiology clinics will increase the use of GDMT. This study is important because it could help improve the use of GDMT, which may lead to improved patient care and outcomes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 3966 (actual)
- First submitted
- 21 Feb 2025
- Start date
- 24 Mar 2025
- Primary completion date
- 15 Jun 2026
- Lead sponsor
- Emory University
- Diseases
- Heart failure
- NCT number
- NCT06847438
What you commit to
- Study type: Interventional
- Participants enrolled: 3966
- From 24 Mar 2025 to the primary completion date, 15 Jun 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Heart failure (HF) etiology for which GDMT is not indicated: including hypertrophic or restrictive cardiomyopathy (e.g. amyloid cardiomyopathy), constrictive pericarditis, or complex congenital heart disease
- End-stage HF requiring continuous inotrope infusion, heart transplant, or left ventricular assist device
- Any conditions other than HF that are likely to alter the patient's status over 6 months, indicated by active hospice status
Lab values
- Estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m\^2
Who the study is looking for
- Ejection fraction (EF) less than or equal to 40% by echocardiogram performed in the prior 18 months
- Diagnosis of heart failure
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory University Hospital Midtown Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Emory Saint Joseph's Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Emory University Hospital Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Emory Johns Creek Hospital Coordinator of this site? Confirm its status | Johns Creek | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.